Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
60%
Ph phase_4
1
20%

Phase Distribution

3

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (75.0%)
Phase 41 (25.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completed

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

NCT02555852
completedphase_1

Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

NCT02232308
completedphase_1

Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

NCT01161940
completedphase_1

Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions

NCT01161927
completedphase_4

Weight Gain Management in Patients With Schizophrenia

NCT00486005

Clinical Trials (5)

Showing 5 of 5 trials
NCT02555852

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Completed
NCT02232308Phase 1

Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

Completed
NCT01161940Phase 1

Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

Completed
NCT01161927Phase 1

Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions

Completed
NCT00486005Phase 4

Weight Gain Management in Patients With Schizophrenia

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5